Stargardt Disease Therapeuticss Market, By Drug Type (Emixustat, LBS-008, others (Gildeuretinol), By Age Group (Children (Below 17 Years) and Adult (Above 17 Years)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),
Description
Stargardt disease also called Stargardt's macular dystrophy (SMD) that affects approximately one in 10,000 people and described as central vision loss early in life. Stargardt Disease is most commonly caused by mutations in the ABCA4 gene located on chromosome 1 and is inherited in an autosomal recessive manner. This disorder affects the specialized light-sensitive tissue present in the retina. This type of macular degeneration affects the center of the retina which is known as macula which adds sharpness to the central vision. The affected individuals also show the symptoms of color blindness. The signs and symptoms appear in late childhood which is responsible for disease progression.
Market Dynamics
The increasing prevalence of stargardt disease is expected to drive the market growth over the forecast period. For instance, according to the article published in the Association for Research in Vision and Ophthalmology journal, the worldwide prevalence of stargardt disease is estimated to be in between 1 in 8,000 to 10,000 individuals.
Furthermore, key players operating in the Global Stargardt Disease Therapeutics Market are focusing on adoption of growth strategies are expected to drive the market growth during the forecast period. For instance, in July 2017, Ophthotech Corporation, a clinical stage company, is adopting a new strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for which there are limited or no treatment options available. Ophthotech’s orphan ophthalmic disease strategy will be led by a randomized, controlled clinical trial assessing the efficacy and safety of Zimura (avacincaptad pegol), the company’s C5 complement inhibitor, for Stargardt disease.
Key features of the study:
Market Dynamics
The increasing prevalence of stargardt disease is expected to drive the market growth over the forecast period. For instance, according to the article published in the Association for Research in Vision and Ophthalmology journal, the worldwide prevalence of stargardt disease is estimated to be in between 1 in 8,000 to 10,000 individuals.
Furthermore, key players operating in the Global Stargardt Disease Therapeutics Market are focusing on adoption of growth strategies are expected to drive the market growth during the forecast period. For instance, in July 2017, Ophthotech Corporation, a clinical stage company, is adopting a new strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for which there are limited or no treatment options available. Ophthotech’s orphan ophthalmic disease strategy will be led by a randomized, controlled clinical trial assessing the efficacy and safety of Zimura (avacincaptad pegol), the company’s C5 complement inhibitor, for Stargardt disease.
Key features of the study:
- This report provides in-depth analysis of the Global Stargardt Disease Therapeutics Market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the Global Stargardt Disease Therapeutics Market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc, Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., F. Hoffmann-La Roche AG.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The Global Stargardt Disease Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Stargardt Disease Therapeutics Market .
- Global Stargardt Disease Therapeutics Market , By Drug Type:
- Emixustat
- LBS-008
- Global Stargardt Disease Therapeutics Market , By Age Group:
- Children (Below17 Years)
- Adult (Above 17 Years)
- Global Stargardt Disease Therapeutics Market , By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Stargardt Disease Therapeutics Market , By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Kubota Pharmaceutical Holdings Co., Ltd.
- Stargazer Pharmaceuticals Inc.
- Iveric Bio, Inc.
- Sanofi S.A.
- Alkeus Pharmaceuticals Inc.
- Astellas Pharma Inc.
- CHABiotech CO., Ltd
- ReVision Therapeutics, Inc.
- Lin BioScience, Inc.
- Biogen Inc.
- Hoffmann-La Roche AG
Table of Contents
167 Pages
- 1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Age Group
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Epidemiology
- 4. Global Stargardt Disease Therapeutics Market – COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
- 5. Global Stargardt Disease Therapeutics Market, By Drug Type, 2020–2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021–2032
- Segment Trends
- Emixustat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Segment Trends
- LBS-008
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Segment Trends
- Others (Gildeuretinol)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Segment Trends
- 6. Global Stargardt Disease Therapeutics Market, By Age Group, 2020–2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021–2032
- Segment Trends
- Children (Below 17 Years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Segment Trends
- Adult (Above 17 Years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Segment Trends
- 7. Global Stargardt Disease Therapeutics Market, By Distribution Channel, 2020–2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021–2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- 8. Global Stargardt Disease Therapeutics Market, By Region, 2020–2032, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021–2032
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- 9. Competitive Landscape
- Company Profiles
- Kubota Pharmaceutical Holdings Co., Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Stargazer Pharmaceuticals Inc.
- Iveric Bio, Inc.
- Sanofi S.A.
- Alkeus Pharmaceuticals Inc.
- Astellas Pharma Inc.
- CHABiotech CO., Ltd
- ReVision Therapeutics, Inc.
- Lin BioScience, Inc.
- Biogen Inc.
- Hoffmann-La Roche AG
- Ocugen, Inc.
- Ascidian Therapeutics
- Nanoscope Therapeutics Inc.
- Aequus Pharmaceuticals Inc.
- Fera Pharmaceuticals, LLC
- Insmed Incorporated
- Belite Bio, Inc.
- SpliceBio
- 10. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 35 market data tables and 30 figures on “Global Stargardt Disease Therapeutics Market” – Global forecast to 2032
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
